Uta Griesenbach, Eric W.F.W. Alton, Department of Gene Therapy, Faculty of Medicine ... proof-of-principle for gene transfer into the cystic fibrosis (CF) lung. It is currently unknown whether ...
"4DMT reveals positive interim Phase I/II data for cystic fibrosis gene therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...
Gene therapy for CF and α1-ATD seeks to produce ... for the damaged originals and revert the disease process. Cystic fibrosis (CF), α1-antitrypsin deficiency (α1-ATD), and surfactant protein ...
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter ...
New breakthroughs in gene editing mean that cures for genetic diseases such as cystic fibrosis could be developed in the near ...
The FDA has approved Vertex’s Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis in people 6 years and older who have mutations that are amenable to the therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback